Rifampicin reduces plasma concentrations of celiprolol

European Journal of Clinical Pharmacology

Volumn 59, Issue 11, 2004, Pages 819-824

  Lilja, J J ^a   Niemi, M ^a,b   Neuvonen, P J ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

Author keywords

Celiprolol; P glycoprotein; Rifampicin

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CELIPROLOL; GLYCOPROTEIN P; RIFAMPICIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG URINE LEVEL; EXON; FEMALE; GENOTYPE; HEART RATE; HEMODYNAMICS; HUMAN; HUMAN EXPERIMENT; KIDNEY CLEARANCE; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN POLYMORPHISM; RANDOMIZED CONTROLLED TRIAL; SITTING; SYSTOLIC BLOOD PRESSURE; URINARY EXCRETION;

ADRENERGIC BETA-ANTAGONISTS; ADULT; ANTIBIOTICS, ANTITUBERCULAR; AREA UNDER CURVE; CELIPROLOL; CROSS-OVER STUDIES; FEMALE; GENOTYPE; HALF-LIFE; HUMANS; MALE; P-GLYCOPROTEIN; POLYMORPHISM, GENETIC; RIFAMPIN;

EID: 1242269897     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-003-0694-z     Document Type: Article

References (30)

1. 450 3A4 inhibition. Clin Pharmacokinet 38:41-57
2. Niemi M, Backman JT, Fromm MF, Neuvonen PJ, Kivistö KT (2003) Pharmacokinetic interactions with rifampicin: clinical relevance. Clin Pharmacokinet 42:819-850
3. Partanen J, Jalava K-M, Neuvonen PJ (1996) Itraconazole increases serum digoxin concentration. Pharmacol Toxicol 79:274-276
4. Greiner B, Eichelbaum M, Fritz P, Kreichgauer HP, von Richter O, Zundler J, Kroemer HK (1999) The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest 104:147-153
5. Lum BL, Gosland MP (1995) MDR expression in normal tissues. Pharmacologic implications for the clinical use of P-glycoprotein inhibitors. Hematol Oncol Clin North Am 9:319-336
6. 450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinogen 13:129-134
7. 450 3A coordinately up-regulate these proteins in human colon carcinoma cells. Mol Pharmacol 49:311-318
8. Riddel JG, Shanks RG, Brogden RN (1987) Celiprolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties and its therapeutic use in hypertension and angina pectoris. Drugs 34:438-458
9. Milne RJ, Buckley MM (1991) Celiprolol. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in cardiovascular disease. Drugs 41:941-969
10. Karlsson J, Kuo S-M, Ziemniak J, Artursson P (1993) Transport of celiprolol across human intestinal epithelial (Caco-2) cells: mediation of secretion by multiple transporters including P-glycoprotein. Br J Pharmacol 110:1009-1016
11. 450 IIIA4 (CYP3A4) in human small bowel enterocytes. J Clin Invest 90:1871-1878
12. Hamman MA, Bruce MA, Haehner-Daniels BD, Hall SD (2001) The effect of rifampin administration on the disposition of fexofenadine. Clin Pharmacol Ther 69:114-121
13. Cabrera K, Lubda D, Eggenweiler H-M, Minakuchi H, Nakanishi K (2000) R&D biochemistry and separation, Merck KgaA: a new monolithic-type HPLC column for fast separations. J High Resolut Chromatogr 23:93-99
14. Chiu FC, Raymond K (1996) Validated assay for the determination of celiprolol in plasma using high-performance liquid chromatography and a silanol deactivated reversed-phase support. J Chromatogr B Biomed Appl 687:462-465
15. Furuno T, Landi MT, Ceroni M, Caporaso N, Bernucci I, Nappi G, Martignini E, Schaeffeler E, Eichelbaum M, Schwab M, Zanger UM (2002) Expression polymorphism of the blood-brain barrier component P-glycoprotein (MDR1) in relation to Parkinson's disease. Pharmacogenetics 12:529-534
16. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmöller J, Johne A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M, Brinkmann U (2000) Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 97:3473-3478
17. Heusser K, Schobel HP, Adamidis A, Fischer T, Frank H (2002) Cardiovascular effects of beta-blockers with and without intrinsic sympathomimetic activity. A comparison between celiprolol and metoprolol. Kidney Blood Press Res 25:34-41
18. Lilja JJ, Backman JT, Laitila J, Luurila H, Neuvonen PJ (2003) Itraconazole increases but grapefruit juice greatly decreases plasma concentrations of celiprolol. Clin Pharmacol Ther 73:192-198
19. Kuo SM, Whitby BR, Artursson P, Ziemniak JA (1994) The contribution of intestinal secretion to the dose-dependent absorption of celiprolol. Pharm Res 11:648-653
20. Westphal K, Weinbrenner A, Zschiesche M, Franke G, Knoke M, Oertel R, Fritz P, von Richter O, Warzok R, Hachenberg T, Kauffmann HM, Schrenk D, Terhaag B, Kroemer HK, Siegmund W (2000) Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: a new type of drug/drug interaction. Clin Pharmacol Ther 68:345-355
21. de Lannoy IA, Silverman M (1992) The MDR1 gene product, P-glycoprotein, mediates the transport of the cardiac glycoside, digoxin. Biochem Biophys Res Commun 189:551-557
22. Spahn-Langguth H, Baktir G, Radschuweit A, Okyar A, Terhaag B, Ader P, Hanafy A, Langguth P (1998) P-glycoprotein transporters and the gastrointestinal tract: evaluation of the potential in vivo relevance of in vitro data employing talinolol as model compound. Int J Clin Pharmacol Ther 36:16-24
23. Cvetkovic M, Leake B, Fromm MF, Wilkinson GR, Kim RB (1999) OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos 27:866-871
24. Fromm MF, Kaufmann H-M, Fritz P, Burk O, Kroemer HK, Warzok RW, Siegmund W, Schrenk D (2000) The effect of rifampin treatment on intestinal expression of human MRP transporters. Am J Pathol 157:1575-1580
25. Geick A, Eichelbaum M, Burk O (2001) Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem 276:14581-14587
26. Zhang H, LeCulyse E, Liu L, Hu M, Matoney L, Zhu W, Yan B (1999) Rat pregnane X receptor: molecular cloning, tissue distribution, and xenobiotic regulation. Arch Biochem Biophys 368:14-22
27. Drescher S, Glaeser H, Mürdter T, Hitzl M, Eichelbaum M, Fromm MF (2003) P-glycoprotein-mediated intestinal and biliary digoxin transport in humans. Clin Pharmacol Ther 73:223-231
28. Cascorbi I, Gerloff T, Johne A, Meisel C, Hoffmeyer S, Schwab M, Schaeffeler E, Eichelbaum M, Brinkmann U, Roots I (2001) Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 69:169-174
29. Verstuyft C, Schwab M, Schaeffeler E, Kerb R, Brinkmann U, Jaillon P, Funck-Brentano C, Becquemont L (2003) Digoxin pharmacokinetics and MDR1 genetic polymorphisms. Eur J Clin Pharmacol 58:809-812
30. Siegmund W, Ludwig K, Giessmann T, Dazert P, Schroeder E, Sperker B, Warzok R, Kroemer HK, Cascorbi I (2002) The effects of the human MDR1 genotype on the expression of duodenal P-glycoprotein and disposition of the probe drug talinolol. Clin Pharmacol Ther 72:572-583